Johnson & Johnson (JNJ)

$206.54 +6.58 (3.29%)
Market Cap 481.76B
Revenue (ttm) 88.82B
Net Income (ttm) 14.07B
EPS (ttm) N/A
PE Ratio 19.42
Forward PE 18.55
Profit Margin 15.84%
Debt to Equity Ratio 0.50
Volume 11,599,700
Avg Vol 8,765,544
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 85%
Beta 0.36
Analysts Strong Sell
Price Target $205.25

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
PittsburghTrader
PittsburghTrader Dec. 11 at 3:31 PM
$MRK $JNJ up almost 2% already
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 11 at 3:29 PM
$JNJ RSI: 67.91, MACD: 3.7231 Vol: 4.25, MA20: 202.81, MA50: 194.28 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 3:25 PM
RBC Capital updates rating for Johnson & Johnson ( $JNJ ) to Outperform, target set at 209 → 230.
0 · Reply
StoxWise369
StoxWise369 Dec. 11 at 2:56 PM
$BEAT Sadly criminals immuned! dropping down to 1.30s shaking out the weak and gullible, many at a loss, then boosting it up after their cronies all loaded?! 🥴imo $LLY $MRK $JNJ
0 · Reply
ElizabethLee1023
ElizabethLee1023 Dec. 11 at 1:54 PM
Piper Sandler raises its price target for $GOOGL Alphabet from $330 to $365 RBC Capital raises its price target for $JNJ Johnson & Johnson from $209 to $230 Bank of America downgrades $PYPL PayPal from Buy to Neutral with a price target of $68
0 · Reply
BioTechHealthX
BioTechHealthX Dec. 11 at 11:50 AM
$JNJ Johnson & Johnson (JNJ) delivered impressive multiple myeloma data that could redefine the oncology market and reshape long-term growth. Learn why new TECVAYLI, DARZALEX FASPRO, and CARVYKTI results are shifting the investment outlook for this iconic healthcare giant. https://biotechhealthx.com/biotech-news/johnson-johnson/
0 · Reply
Marisatap
Marisatap Dec. 11 at 9:50 AM
$JNJ
0 · Reply
DeadInvestor
DeadInvestor Dec. 11 at 3:21 AM
$TVTX 69% of todays Volume was short trades. 68% yesterday. Crazy in my view. FSGS label expansion approval is 4 weeks away, and will be catalyst to mid $40’s. Then in Feb, I expect a buyout in the $55 to $65 range. $NVS and $LLY are front runners. $JNJ and $AZN also in the hunt. Giddy up.
0 · Reply
TheStockTraderHub
TheStockTraderHub Dec. 11 at 1:56 AM
$JNJ looks ready for another leg up 📈
1 · Reply
Trend_Mapper
Trend_Mapper Dec. 10 at 10:15 PM
$JNJ forming constructive behavior as the pace improves
0 · Reply
Latest News on JNJ
GS Equity Income Fund: Q3 2025 Witnesses Fundamental Strength And Expansive Margin Opportunities

Dec 9, 2025, 9:50 PM EST - 1 day ago

GS Equity Income Fund: Q3 2025 Witnesses Fundamental Strength And Expansive Margin Opportunities

ACN DHI HON KVUE ORCL SSB WFC

5 defensive stocks traders are buying before the Fed rate-cut decision

Dec 9, 2025, 12:18 PM EST - 1 day ago

5 defensive stocks traders are buying before the Fed rate-cut decision

DUK KO NEE PG

1 Major Factor Behind the Healthcare Sector's Recent Surge

Dec 9, 2025, 10:55 AM EST - 1 day ago

1 Major Factor Behind the Healthcare Sector's Recent Surge

ABBV LLY MRK

Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma

Dec 9, 2025, 7:44 AM EST - 2 days ago

Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma

Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 8, 2025, 4:25 PM EST - 2 days ago

Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma

Dec 6, 2025, 9:30 AM EST - 5 days ago

Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma

Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC

Dec 5, 2025, 4:20 PM EST - 5 days ago

Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC

Johnson & Johnson (JNJ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 2:13 PM EST - 7 days ago

Johnson & Johnson (JNJ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

American Century Value Fund Q3 2025 Contributors/Detractors And Notable Trades

Dec 1, 2025, 1:36 PM EST - 9 days ago

American Century Value Fund Q3 2025 Contributors/Detractors And Notable Trades

BWA CNC CRM KVUE LMT NVT TER

16 Quality Stocks to Own for a Volatile Market

Dec 1, 2025, 1:23 PM EST - 9 days ago

16 Quality Stocks to Own for a Volatile Market

CSCO LLY XOM

Johnson & Johnson receives European Commission approval of IMAAVY® (nipocalimab), a new FcRn blocker offering sustained disease control in a broad population of people living with generalised myasthenia gravis (gMG)

Dec 1, 2025, 8:18 AM EST - 10 days ago

Johnson & Johnson receives European Commission approval of IMAAVY® (nipocalimab), a new FcRn blocker offering sustained disease control in a broad population of people living with generalised myasthenia gravis (gMG)

3 Stocks to Buy and Hold: the Long-Term Play for Your Portfolio

Nov 30, 2025, 6:30 AM EST - 11 days ago

3 Stocks to Buy and Hold: the Long-Term Play for Your Portfolio

MDT PFE

2 Top Dividend Stocks to Buy and Hold

Nov 30, 2025, 4:05 AM EST - 11 days ago

2 Top Dividend Stocks to Buy and Hold

BMY

Best Dividend Aristocrats For December 2025

Nov 29, 2025, 8:02 AM EST - 12 days ago

Best Dividend Aristocrats For December 2025

ABBV ABT ADM ADP AFL ALB AMCR

Dogs Of The Dow Continue Outperforming Broader Market

Nov 29, 2025, 1:45 AM EST - 12 days ago

Dogs Of The Dow Continue Outperforming Broader Market

AMGN DIA MAGS SPY

Wasatch Global Value Fund Q3 2025 Performance Review

Nov 28, 2025, 7:50 AM EST - 13 days ago

Wasatch Global Value Fund Q3 2025 Performance Review

BABA CNC DOX NVDA

3 Superb Dividend Stocks to Hold for the Next 20 Years

Nov 27, 2025, 6:30 AM EST - 14 days ago

3 Superb Dividend Stocks to Hold for the Next 20 Years

KO O

Have $2,000 to Invest? Here Are 4 of My Favorite Dividend Stocks for the Next 5 Years

Nov 27, 2025, 4:01 AM EST - 14 days ago

Have $2,000 to Invest? Here Are 4 of My Favorite Dividend Stocks for the Next 5 Years

HD O PFE

JNJ Stock vs. PFE Stock: Which Pharmaceutical Giant Is A Better Buy?

Nov 25, 2025, 5:20 AM EST - 16 days ago

JNJ Stock vs. PFE Stock: Which Pharmaceutical Giant Is A Better Buy?

PFE

1 Reason Why Shares of Johnson & Johnson Are Surging This Month

Nov 21, 2025, 12:43 PM EST - 19 days ago

1 Reason Why Shares of Johnson & Johnson Are Surging This Month

Why Johnson & Johnson's Share Price Is Popping This Month

Nov 19, 2025, 12:24 PM EST - 21 days ago

Why Johnson & Johnson's Share Price Is Popping This Month

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

Nov 18, 2025, 4:21 PM EST - 22 days ago

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

AZN LLY MDT MRK NVO OLMA PFE

Global drugmakers rush to boost US presence as tariff threat looms

Nov 18, 2025, 8:25 AM EST - 23 days ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN BIIB GILD GSK LLY

Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy

Nov 17, 2025, 6:07 PM EST - 23 days ago

Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy

Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Nov 17, 2025, 1:17 PM EST - 23 days ago

Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion

Nov 17, 2025, 8:29 AM EST - 24 days ago

Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion

Halda Therapeutics Announces Acquisition by Johnson & Johnson

Nov 17, 2025, 8:15 AM EST - 24 days ago

Halda Therapeutics Announces Acquisition by Johnson & Johnson

J&J to buy cancer therapy developer Halda Therapeutics for $3.05 billion

Nov 17, 2025, 8:07 AM EST - 24 days ago

J&J to buy cancer therapy developer Halda Therapeutics for $3.05 billion

New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis

Nov 17, 2025, 8:05 AM EST - 24 days ago

New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis

Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics

Nov 17, 2025, 8:00 AM EST - 24 days ago

Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

Nov 14, 2025, 3:19 PM EST - 26 days ago

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

ABBV AZN LLY MRK NVO PFE XLV

Bristol Myers, J&J halt heart drug trial after interim review

Nov 14, 2025, 8:03 AM EST - 27 days ago

Bristol Myers, J&J halt heart drug trial after interim review

BMY

2 Healthcare Stocks for Beginner Investors With a 40-Year Time Horizon

Nov 13, 2025, 5:04 AM EST - 4 weeks ago

2 Healthcare Stocks for Beginner Investors With a 40-Year Time Horizon

ISRG

2 Strong Healthcare Stock Picks for Dividend Investors

Nov 13, 2025, 3:55 AM EST - 4 weeks ago

2 Strong Healthcare Stock Picks for Dividend Investors

ABBV

Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.

Nov 12, 2025, 11:01 AM EST - 4 weeks ago

Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.

CVS

Johnson & Johnson (JNJ) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 11, 2025, 1:41 PM EST - 4 weeks ago

Johnson & Johnson (JNJ) Presents at UBS Global Healthcare Conference 2025 Transcript

Johnson & Johnson (JNJ) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Nov 11, 2025, 12:51 PM EST - 4 weeks ago

Johnson & Johnson (JNJ) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Johnson & Johnson: 2 Recent FDA Wins And Earnings Beat Warrant 'Buy' Rating

Nov 10, 2025, 6:26 AM EST - 4 weeks ago

Johnson & Johnson: 2 Recent FDA Wins And Earnings Beat Warrant 'Buy' Rating

Got $1,000? Here Are the Smartest Dividend Stocks to Start With.

Nov 10, 2025, 4:15 AM EST - 4 weeks ago

Got $1,000? Here Are the Smartest Dividend Stocks to Start With.

AWR BDX GPC KO MZTI NWN PG

FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression

Nov 7, 2025, 12:57 PM EST - 4 weeks ago

FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression

Johnson & Johnson: Dividends Don't Lie

Nov 7, 2025, 5:40 AM EST - 4 weeks ago

Johnson & Johnson: Dividends Don't Lie

DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma

Nov 6, 2025, 5:07 PM EST - 4 weeks ago

DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma

Cramer's Mad Dash: Johnson & Johnson

Nov 6, 2025, 9:54 AM EST - 5 weeks ago

Cramer's Mad Dash: Johnson & Johnson

US FDA expands use of J&J's Caplyta as add-on depression drug

Nov 6, 2025, 7:34 AM EST - 5 weeks ago

US FDA expands use of J&J's Caplyta as add-on depression drug

FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder

Nov 6, 2025, 7:30 AM EST - 5 weeks ago

FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder

Johnson & Johnson to Participate in the Citi's 2025 Global Healthcare Conference

Nov 5, 2025, 4:50 PM EST - 5 weeks ago

Johnson & Johnson to Participate in the Citi's 2025 Global Healthcare Conference

Will President Trump's Tylenol Claims Hurt These 2 Leading Pharmaceutical Stocks?

Nov 3, 2025, 6:15 AM EST - 5 weeks ago

Will President Trump's Tylenol Claims Hurt These 2 Leading Pharmaceutical Stocks?

KVUE

Best Dividend Aristocrats For November 2025

Nov 1, 2025, 10:25 AM EDT - 5 weeks ago

Best Dividend Aristocrats For November 2025

ABBV ABT ADM ADP AMCR AOS ATO

Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting

Oct 29, 2025, 8:05 AM EDT - 6 weeks ago

Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting

Best Dividend Kings: October 2025

Oct 29, 2025, 5:11 AM EDT - 6 weeks ago

Best Dividend Kings: October 2025

ABBV ABM ABT ADM ADP AWR BDX

PittsburghTrader
PittsburghTrader Dec. 11 at 3:31 PM
$MRK $JNJ up almost 2% already
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 11 at 3:29 PM
$JNJ RSI: 67.91, MACD: 3.7231 Vol: 4.25, MA20: 202.81, MA50: 194.28 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 3:25 PM
RBC Capital updates rating for Johnson & Johnson ( $JNJ ) to Outperform, target set at 209 → 230.
0 · Reply
StoxWise369
StoxWise369 Dec. 11 at 2:56 PM
$BEAT Sadly criminals immuned! dropping down to 1.30s shaking out the weak and gullible, many at a loss, then boosting it up after their cronies all loaded?! 🥴imo $LLY $MRK $JNJ
0 · Reply
ElizabethLee1023
ElizabethLee1023 Dec. 11 at 1:54 PM
Piper Sandler raises its price target for $GOOGL Alphabet from $330 to $365 RBC Capital raises its price target for $JNJ Johnson & Johnson from $209 to $230 Bank of America downgrades $PYPL PayPal from Buy to Neutral with a price target of $68
0 · Reply
BioTechHealthX
BioTechHealthX Dec. 11 at 11:50 AM
$JNJ Johnson & Johnson (JNJ) delivered impressive multiple myeloma data that could redefine the oncology market and reshape long-term growth. Learn why new TECVAYLI, DARZALEX FASPRO, and CARVYKTI results are shifting the investment outlook for this iconic healthcare giant. https://biotechhealthx.com/biotech-news/johnson-johnson/
0 · Reply
Marisatap
Marisatap Dec. 11 at 9:50 AM
$JNJ
0 · Reply
DeadInvestor
DeadInvestor Dec. 11 at 3:21 AM
$TVTX 69% of todays Volume was short trades. 68% yesterday. Crazy in my view. FSGS label expansion approval is 4 weeks away, and will be catalyst to mid $40’s. Then in Feb, I expect a buyout in the $55 to $65 range. $NVS and $LLY are front runners. $JNJ and $AZN also in the hunt. Giddy up.
0 · Reply
TheStockTraderHub
TheStockTraderHub Dec. 11 at 1:56 AM
$JNJ looks ready for another leg up 📈
1 · Reply
Trend_Mapper
Trend_Mapper Dec. 10 at 10:15 PM
$JNJ forming constructive behavior as the pace improves
0 · Reply
StoxWise369
StoxWise369 Dec. 10 at 8:50 PM
$BEAT Hully up! Moo et! Net goh uh mama 😂🤣😩🤣🤣🤣 $LLY $JNJ $MRK
0 · Reply
CowBoE
CowBoE Dec. 10 at 8:00 PM
$CURE $GDRX $JNJ $DXCM $UNH Healthcare is nearly all green.
0 · Reply
JohnGadwin
JohnGadwin Dec. 10 at 7:45 PM
$ABEO unusual option activity $XBI $JNJ $LLY
0 · Reply
ripster47
ripster47 Dec. 10 at 4:54 PM
$JPM $JNJ 🚀 Most folks won't even have these names on watchlist but like i teach about Day2 Repeatable setups these were our TOP Watches, Plan the Trade in Premarket and Trade the Plan! Big winners for community Dn't forget Pscyh Level Strategy, Even a small kid can trade!
0 · Reply
ripster47
ripster47 Dec. 10 at 4:46 PM
🚨 $JPM vs 300 $JNJ vs 200 All you needed so far! Our top plays! Recap later @TENETTRADEGROUP Psych Level Strategy!
0 · Reply
IN0V8
IN0V8 Dec. 10 at 4:25 PM
$JNJ Buy HSBC raises target price to $240 from $215
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 10 at 3:59 PM
Enter: $JNJ Calls Strike Price: $205 Expiry Date: JAN 02 2026 Buy in Price: $2.15 - $2.17 Sell Price: $3.86 Profit : +78% (Turn every $1 into $1.78) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
ZacksResearch
ZacksResearch Dec. 10 at 2:04 PM
$JNJ pulling ahead of $PFE — but is this the moment to lean into the name? Rising estimates and stronger expected 2025 momentum are giving JNJ the edge in this blue-chip battle, even as both companies face patent cliffs and policy headwinds. Full matchup breakdown here 👉 https://www.zacks.com/stock/news/2802052/jnj-vs-pfe-which-blue-chip-drug-stock-is-the-better-investment-now?cid=sm-stocktwits-2-2802052-teaser-24159&ADID=SYND_STOCKTWITS_TWEET_2_2802052_TEASER_24159
0 · Reply
Quantumup
Quantumup Dec. 10 at 2:04 PM
H.C. Wainwright y'day⬆️ $IMMX's PT to $12 from $8, plus⬆️PoS to 85% and reiterated at a Buy rating. $PRTA $AZN $JNJ ABBV $TAK BMY SNY Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/1998754299422122357?s=20
0 · Reply
guidottiztx
guidottiztx Dec. 10 at 12:11 PM
Carvykti strength holds, Legend Biotech weakness overdone, says RBC Capital $LEGN $JNJ
0 · Reply
ZacksResearch
ZacksResearch Dec. 10 at 11:50 AM
Which healthcare giant is the better bet: $JNJ or $PFE? 🤔 J&J shines with a diversified model, strong cash flows, and impressive stock price increase of 38.3% YTD. Meanwhile, Pfizer's attractive valuation and 6.8% dividend yield can't be ignored, even as it faces a rocky patent cliff ahead and challenges in COVID product sales. Discover which stock stands out as the better pick here 👉 https://www.zacks.com/stock/news/2802052/jnj-vs-pfe-which-blue-chip-drug-stock-is-the-better-investment-now?cid=sm-stocktwits-2-2802052-body-24125&ADID=SYND_STOCKTWITS_TWEET_2_2802052_BODY_24125
0 · Reply
10_100_1000
10_100_1000 Dec. 10 at 10:41 AM
$MRNA $SPY $LLY $JNJ $EXAS LNAI SIGNIFICANT TUMOR REGRESSION Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy https://finviz.com/news/238325/lunai-bioworks-secures-first-licensing-loi-following-landmark-breakthrough-showing-complete-tumor-regression-in-humanized-cancer-models
0 · Reply